California-based AI drug discovery company PostEra has raised USD 24 million in a Series A funding round led by The Clermont Group, with participation from new investors Breyer Capital and Lifeforce Capital, and existing investors HOF Capital and Pioneer Fund, among others.
The proceeds will be used to further develop its medicinal chemistry platform, establish its own drug discovery pipeline, and advance its collaborative drug discovery programs.
<ul><li> Simultaneously, the company also extended its multi-year strategic partnership with Pfizer entered in December 2020 , to establish an AI lab. The lab will leverage Pfizer’s drug discovery expertise and data, together with PostEra’s AI technology, to work on a number of drug discovery programs across oncology and Covid-19.</ul>
As part of the renewed deal, PostEra will receive an upfront payment of USD 13 million, followed by up to USD 248 million in additional milestones and other tiered royalties.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.